Pioneer Hub is a practical resource for clinicians looking for clear, concise guidance on using biomarker-driven approaches in the routine care of patients with advanced prostate cancer.
Why focus on biomarker-driven approaches?
Optimize patient outcomes
Despite advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) progress to metastatic castration-resistant prostate cancer (mCRPC), with a median survival of 2–3 years.1–3
Understanding biomarker-driven mechanisms of resistance can provide important information about patient prognosis in metastatic prostate cancer.4–6
Precision medicine strategies
Biomarker testing is an increasingly important tool to inform personalized treatment strategies.7
Despite guideline recommendations, biomarker-driven approaches are underutilized, leading to missed potential opportunities to improve patient outcomes.8
Advance disease understanding
PTEN deficiency leading to PI3K/AKT pathway activation is a common path to disease progression in prostate cancer.9
Testing for PTEN deficiency, a prognostic biomarker, can identify more aggressive forms of mHSPC and may allow for future biomarker-driven treatment strategies, before progression to mCRPC.5,9
Explore key pages
AKT, protein kinase B; mCRPC, metastatic castration-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog.
1. Ng K, et al. Oncol Ther. 2020;8(2):209–230; 2. Freedland SJ, et al. Prostate Cancer Prostatic Dis. 2024;27(2):327–333; 3. Moreira DM, et al. Clin Genitourin Cancer. 2017;15(1):60–66; 4. Chandrasekar T, et al. Transl Androl Urol. 2015;4(3):365–380; 5. Zhang JY, et al. Asian J Androl. 2022;24(1):50–55; 6. Jamaspishvili T, et al. Nat Rev Urol. 2018;15(4):222–234; 7. Pulido R, et al. Cold Spring Harb Perspect Med. 2019;9(12):a036293; 8. Vasudevan A, et al. J Clin Oncol. 2024;42:91; 9. Turnham DJ, et al. Cells. 2020;9(11):2342.
